Literature DB >> 35006499

Associations Between Fundus Types and Clinical Manifestations in Patients with RDH12 Gene Mutations.

Jing Jin1,2,3, Liang Liang3, Kun Jin3, Hai-Jiang Zhang3, Rong Liu4, Yin Shen5,6.   

Abstract

To study the associations between RDH12 gene mutations, fundus types, and clinical manifestations. In total, 46 patients with inherited eye diseases caused by RDH12 gene mutations were included in this study. High-throughput chip capture sequencing, Sanger sequencing, and gene panel detection were used to determine that RDH12 was the pathogenic gene. All patients underwent the following detailed ophthalmic examinations: visual acuity, visual field, intraocular pressure, fundus photography, electroretinography, and optical coherence tomography (OCT). Statistical analysis was used to evaluate the clinical phenotype. A total of 32 mutations were identified in 46 patients. The most common mutations were c.437T > A, c.184C > T, and c.524C > T; the corresponding amino acid changes were p.Val146Asp, p.Arg62Ter, and p.Ser175Leu. Of the 46 patients, retinitis pigmentosa (RP) was found in 31 (68.9%); leber congenital amaurosis (LVA) was found in 11 (24.4%); early onset of severe retinal dystrophy (EOSRD) was found in one (2.2%); cone rod dystrophy (CORD) was found in one (2.2%); and Stargardt disease was found in one (2.2%). There was a significant difference in best-corrected visual acuity among patients based on fundus type (p = 0.0124). Linear trend analysis showed that best-corrected visual acuity gradually decreased as the fundus type increased in severity. In addition, there was a significant difference in the incidence of night blindness among patients with different fundus types (p = 0.0429): types I and IV fundi were associated with the highest incidences of night blindness. RDH12 gene mutation can cause serious inherited retinal diseases, which primarily include RP and LCA. Combined with clinical symptoms and fundus types, the progression of the disease can be characterized and used to guide genetic diagnosis and gene therapy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Fundus features; Gene mutation; Leber congenital amaurosis; RDH12; Retinitis pigmentosa

Mesh:

Substances:

Year:  2022        PMID: 35006499     DOI: 10.1007/s10548-021-00885-7

Source DB:  PubMed          Journal:  Brain Topogr        ISSN: 0896-0267            Impact factor:   4.275


  35 in total

Review 1.  Retinitis pigmentosa: recent advances and future directions in diagnosis and management.

Authors:  Abigail Fahim
Journal:  Curr Opin Pediatr       Date:  2018-12       Impact factor: 2.856

2.  Prevalence of generalized retinal dystrophy in Denmark.

Authors:  Mette Bertelsen; Hanne Jensen; Jesper F Bregnhøj; Thomas Rosenberg
Journal:  Ophthalmic Epidemiol       Date:  2014-06-25       Impact factor: 1.648

3.  Rdh12 activity and effects on retinoid processing in the murine retina.

Authors:  Jared D Chrispell; Kecia L Feathers; Maureen A Kane; Chul Y Kim; Matthew Brooks; Ritu Khanna; Ingo Kurth; Christian A Hübner; Andreas Gal; Alan J Mears; Anand Swaroop; Joseph L Napoli; Janet R Sparrow; Debra A Thompson
Journal:  J Biol Chem       Date:  2009-06-08       Impact factor: 5.157

4.  Population genetic studies of retinitis pigmentosa.

Authors:  J A Boughman; P M Conneally; W E Nance
Journal:  Am J Hum Genet       Date:  1980-03       Impact factor: 11.025

Review 5.  Natural History and Genotype-Phenotype Correlations in RDH12-Associated Retinal Degeneration.

Authors:  Abigail T Fahim; Debra A Thompson
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

6.  RDH12 Mutations Cause a Severe Retinal Degeneration With Relatively Spared Rod Function.

Authors:  Tomas S Aleman; Katherine E Uyhazi; Leona W Serrano; Vidyullatha Vasireddy; Scott J Bowman; Michael J Ammar; Denise J Pearson; Albert M Maguire; Jean Bennett
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-10-01       Impact factor: 4.799

7.  Development of a Gene Therapy Vector for RDH12-Associated Retinal Dystrophy.

Authors:  Kecia L Feathers; Lin Jia; Nirosha Dayanthi Perera; Adrienne Chen; Feriel K Presswalla; Naheed W Khan; Abigail T Fahim; Alexander J Smith; Robin R Ali; Debra A Thompson
Journal:  Hum Gene Ther       Date:  2019-08-05       Impact factor: 5.695

8.  Long-term effect of gene therapy on Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Manjit S Mehat; Venki Sundaram; Scott J Robbie; Susie E Barker; Caterina Ripamonti; Anastasios Georgiadis; Freya M Mowat; Stuart G Beattie; Peter J Gardner; Kecia L Feathers; Vy A Luong; Suzanne Yzer; Kamaljit Balaggan; Ananth Viswanathan; Thomy J L de Ravel; Ingele Casteels; Graham E Holder; Nick Tyler; Fred W Fitzke; Richard G Weleber; Marko Nardini; Anthony T Moore; Debra A Thompson; Simon M Petersen-Jones; Michel Michaelides; L Ingeborgh van den Born; Andrew Stockman; Alexander J Smith; Gary Rubin; Robin R Ali
Journal:  N Engl J Med       Date:  2015-05-04       Impact factor: 91.245

Review 9.  Leber Congenital Amaurosis (LCA): Potential for Improvement of Vision.

Authors:  Artur V Cideciyan; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-04-01       Impact factor: 4.799

Review 10.  Genes and mutations causing retinitis pigmentosa.

Authors:  S P Daiger; L S Sullivan; S J Bowne
Journal:  Clin Genet       Date:  2013-06-19       Impact factor: 4.438

View more
  2 in total

Review 1.  Genetic dissection of non-syndromic retinitis pigmentosa.

Authors:  Aarti Bhardwaj; Anshu Yadav; Manoj Yadav; Mukesh Tanwar
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

2.  Clinical and Genetic Analysis of RDH12-Associated Retinopathy in 27 Chinese Families: A Hypomorphic Allele Leads to Cone-Rod Dystrophy.

Authors:  Junwen Wang; Yingwei Wang; Shiqiang Li; Xueshan Xiao; Zhen Yi; Yi Jiang; Xueqing Li; Xiaoyun Jia; Panfeng Wang; Chenjin Jin; Wenmin Sun; Qingjiong Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-08-02       Impact factor: 4.925

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.